Business
Phathom Pharmaceuticals Announces Leadership Succession
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and
About this update from Phathom Pharmaceuticals, Inc.
[{"type":"text","content":"FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reasons. “We are excited to welcome Steve to Phathom during this important growth period for our Company,” said Michael Cola, Chairman of Phathom. “Steve is an accomplished biopharmaceutical leader with a strong track record of developing and commercializing novel treatments and building growth-oriented organizations. To expand upon Phathom’s strong foundation, the Board seeks to further accelerate our commercial growth and believes Steve’s breadth of experience, extensive commercial expertise and passion for bringing novel therapies to patients will be extremely valuable as we continue getting VOQUEZNA® in the hands of patients in need. We are confident Steve is the right leader to take Phathom to the next level and look forward to working with him to expand opportunities for VOQUEZNA, deliver critical treatments for patients and drive enhanced shareholder value.” “I am thrilled to lead Phathom through this next phase of the Company’s commercial journey,” Mr. Basta said. “The Phathom team has only just begun to unlock the full potential of VOQUEZNA to treat the significant unmet needs of patients with GI diseases. This market needs innovative treatment options, and I believe Phathom is uniquely positioned to capture the significant opportunities that lie ahead. I look forward to leveraging my experience in new product development, commercial strategy, sales and operations to accelerate growth and positively impact patients’ lives.” Ms. Curran commented, “It has been an honor to serve as Phathom’s CEO over the past five years. I am proud of what our team has achieved to change the treatment landscape for patients suffering from GI diseases. It has been a remarkable journey, and I am grateful for the team’s dedication and support for our mission. I’m confident the Company is well positioned for growth and many more accomplishments...